DRG Epidemiology’s coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of NAFLD for each…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
To determine the trade-offs across key biosimilar attributes that surveyed rheumatologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-based…
To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-…
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and…
In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of Alzheimer’s Disease (AD), rendering it the first potential DMT…
Approved therapies for Alzheimer's disease (AD) comprise symptomatic agents (e.g., donepezil, memantine) that provide only modest cognitive benefit for a limited period of time. A rapidly…